In preclinical studies, afatinib and dacomitinib are effective to tumor harbouring T790M mutation and wide-type (WT) EGFR, although the IC50 is 10–500 fold higher than EGFR sensitive mutation alone [5–7]. This evidence concerns the gene EGFR and neoplasm.